These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. BF066, a novel dual target antiplatelet agent without significant bleeding. Pan C; Wei X; Ye J; Liu G; Zhang S; Zhang Y; Du H; Ding Z PLoS One; 2012; 7(7):e40451. PubMed ID: 22815749 [TBL] [Abstract][Full Text] [Related]
3. DL-3-n-butylphthalide inhibits platelet activation via inhibition of cPLA2-mediated TXA2 synthesis and phosphodiesterase. Ye J; Zhai L; Zhang S; Zhang Y; Chen L; Hu L; Zhang S; Ding Z Platelets; 2015; 26(8):736-44. PubMed ID: 25734213 [TBL] [Abstract][Full Text] [Related]
4. 1, 6-di-O-caffeoyl-β-D-glucopyranoside, a natural compound from Callicarpa nudiflora Hook impairs P2Y Fu J; Zhu X; Wang W; Lu H; Zhang Z; Liu T; Xu H; Fu H; Ma S; Luo Y Phytomedicine; 2017 Dec; 36():273-282. PubMed ID: 29157825 [TBL] [Abstract][Full Text] [Related]
5. Antiplatelet Activity of a Newly Synthesized Novel Ruthenium (II): A Potential Role for Akt/JNK Signaling. Khamrang T; Hung KC; Hsia CH; Hsieh CY; Velusamy M; Jayakumar T; Sheu JR Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28448438 [TBL] [Abstract][Full Text] [Related]
6. BF061, a novel antiplatelet and antithrombotic agent targeting P2Y₁₂ receptor and phosphodiesterase. Hu L; Fan Z; Du H; Ni R; Zhang S; Yin K; Ye J; Zhang Y; Wei X; Zhang X; Gross PL; Kunapuli SP; Ding Z Thromb Haemost; 2011 Dec; 106(6):1203-14. PubMed ID: 21946947 [TBL] [Abstract][Full Text] [Related]
7. Timosaponin AIII induces antiplatelet and antithrombotic activity via Gq-mediated signaling by the thromboxane A2 receptor. Cong Y; Wang L; Peng R; Zhao Y; Bai F; Yang C; Liu X; Wang D; Ma B; Cong Y Sci Rep; 2016 Dec; 6():38757. PubMed ID: 27934923 [TBL] [Abstract][Full Text] [Related]
8. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets. Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910 [TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of luteolin‑4'‑O‑β‑D‑glucopyranoside on P2Y12 and thromboxane A2 receptor‑mediated amplification of platelet activation in vitro. Xu H; Lu H; Zhu X; Wang W; Zhang Z; Fu H; Ma S; Luo Y; Fu J Int J Mol Med; 2018 Jul; 42(1):615-624. PubMed ID: 29693158 [TBL] [Abstract][Full Text] [Related]
10. Antiplatelet effect of catechol is related to inhibition of cyclooxygenase, reactive oxygen species, ERK/p38 signaling and thromboxane A2 production. Chang MC; Chang HH; Wang TM; Chan CP; Lin BR; Yeung SY; Yeh CY; Cheng RH; Jeng JH PLoS One; 2014; 9(8):e104310. PubMed ID: 25122505 [TBL] [Abstract][Full Text] [Related]
11. Skepinone-L, a novel potent and highly selective inhibitor of p38 MAP kinase, effectively impairs platelet activation and thrombus formation. Borst O; Walker B; Münzer P; Russo A; Schmid E; Faggio C; Bigalke B; Laufer S; Gawaz M; Lang F Cell Physiol Biochem; 2013; 31(6):914-24. PubMed ID: 23817201 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor. Yu SM; Wu TS; Teng CM Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768 [TBL] [Abstract][Full Text] [Related]
13. Rho-kinase regulates human platelet activation induced by thromboxane A2 independently of p38 MAP kinase. Iida Y; Doi T; Tokuda H; Matsushima-Nishiwaki R; Tsujimoto M; Kuroyanagi G; Yamamoto N; Enomoto Y; Tanabe K; Otsuka T; Iwama T; Ogura S; Kozawa O; Iida H Prostaglandins Leukot Essent Fatty Acids; 2015 Mar; 94():73-81. PubMed ID: 25500336 [TBL] [Abstract][Full Text] [Related]
14. A novel thromboxane receptor antagonist, nstpbp5185, inhibits platelet aggregation and thrombus formation in animal models. Huang SW; Kuo HL; Hsu MT; Tseng YJ; Lin SW; Kuo SC; Peng HC; Lien JC; Huang TF Thromb Haemost; 2016 Aug; 116(2):285-99. PubMed ID: 27173725 [TBL] [Abstract][Full Text] [Related]
15. The phospholipase C inhibitor U73122 inhibits phorbol ester-induced platelet activation. Lockhart LK; McNicol A J Pharmacol Exp Ther; 1999 May; 289(2):721-8. PubMed ID: 10215645 [TBL] [Abstract][Full Text] [Related]
16. The protective effects of paclitaxel on platelet aggregation through the inhibition of thromboxane A2 synthase. Lee JJ; Yu JY; Lee JH; Zhang WY; Kim TJ; Myung CS; Yun YP Arch Pharm Res; 2010 Mar; 33(3):387-94. PubMed ID: 20361303 [TBL] [Abstract][Full Text] [Related]
18. KRDS, a peptide derived from human lactotransferrin, inhibits thrombin-induced thromboxane synthesis by a cyclooxygenase-independent mechanism. Lévy-Toledano S; Grelac F; Caen JP; Maclouf J Thromb Haemost; 1995 May; 73(5):857-61. PubMed ID: 7482416 [TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of TA-993 and its metabolite MB3 on platelet activation induced by collagen and U-46619 in human platelets. Katoh M; Karasawa T; Watanabe A; Takagi M; Ikeo T; Odawara A Biol Pharm Bull; 2001 May; 24(5):501-4. PubMed ID: 11379769 [TBL] [Abstract][Full Text] [Related]
20. Antiplatelet effect of phloroglucinol is related to inhibition of cyclooxygenase, reactive oxygen species, ERK/p38 signaling and thromboxane A2 production. Chang MC; Chang HH; Chan CP; Chou HY; Chang BE; Yeung SY; Wang TM; Jeng JH Toxicol Appl Pharmacol; 2012 Sep; 263(3):287-95. PubMed ID: 22789837 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]